Literature DB >> 6232084

Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

R N Jones, A L Barry.   

Abstract

Norfloxacin is a new organic acid antimicrobic with an expanded spectrum that includes Staphylococcus spp, most Pseudomonas spp, Acinetobacter calcoaceticus ssp anitratus, some streptococci, as well as nearly all enteric bacilli. The drug appears to be bactericidal. Its expanded spectrum suggests that it should be tested separately by disk diffusion or other susceptibility testing methods. Tentative norfloxacin disk test quality control limits were derived from the results of a multi-laboratory study: Escherichia coli, 28-36 mm; S. aureus, 17-28 mm, and Pseudomonas aeruginosa, 22-29 mm.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6232084     DOI: 10.1016/0732-8893(83)90047-0

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  Tentative disk diffusion susceptibility interpretive criteria for pefloxacin.

Authors:  P C Fuchs; A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

3.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  Multicenter evaluation of the proposed quality control limits and interpretive zone standards for in vitro susceptibility testing with norfloxacin.

Authors:  D L Shungu; V Tutlane; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

5.  In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa.

Authors:  J Righter
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

Review 7.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

8.  Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.

Authors:  D Gargallo; M Moros; R Coll; M Esteve; J Parés; M A Xicota; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.